Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Bridgebio Pharma Inc's Business Segments
Bridgebio Pharma Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 244
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2026
- Reportable100%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 244 | 100% |
Revenue by Product & Service Category - Q2 FY2026
- Product91.3%
- Royalty6.3%
- License and Service2.4%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 222 | 91.3% |
| Royalty | $ 15 | 6.3% |
| License and Service | $ 6 | 2.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Bridgebio Pharma Inc
BridgeBio Pharma Inc. is a biopharmaceutical company that focuses on developing and commercializing therapies for genetic diseases. Founded in 2015, the company aims to address serious and rare diseases by targeting the underlying genetic causes. BridgeBio Pharma operates with a unique model called the hub and spoke model, where it combines its internal discovery platforms with collaborations with external partners to develop and advance a diverse portfolio of therapies.
The company's portfolio includes multiple product candidates at different stages of development, ranging from early-stage research to late-stage clinical trials. BridgeBio Pharma is involved in various therapeutic areas, including oncology, cardiology, dermatology, neurology, endocrinology, and more. Their extensive pipeline includes potential treatments for diseases like genetic dermatology disorders, genetic cardiac diseases, lysosomal storage disorders, and various types of cancer.
One of the distinctive features of BridgeBio Pharma is its focus on genetically driven diseases that have limited treatment options or no approved therapies available. These genetic diseases are often caused by specific mutations or gene abnormalities, and BridgeBio Pharma's approach is to develop targeted therapies that can correct or mitigate these genetic defects. By using proprietary technologies and research capabilities, the company aims to uncover novel drug targets and develop innovative treatment strategies.
In addition to their internal research and development efforts, BridgeBio Pharma has established partnerships and collaborations with renowned academic institutions, pharmaceutical companies, and other biotech companies. This approach allows them to leverage external expertise, resources, and technologies to complement their own capabilities and accelerate the development of potential therapies.
BridgeBio Pharma applies a patient-centered approach to its drug development process. The company works closely with patient advocacy groups and aims to understand the specific needs of patients suffering from genetic diseases. By engaging with the patient community, BridgeBio Pharma seeks to bring meaningful and impactful therapies to market that can improve the lives of patients and their families.
As a publicly traded company, BridgeBio Pharma has a strong financial footing. The company has received significant investments from reputable investors, which provide the necessary capital for research and development activities. Furthermore, their collaborations with pharmaceutical companies also include financial support in the form of milestone payments and royalties.
In summary, BridgeBio Pharma Inc. is a biopharmaceutical company focused on providing therapeutic solutions for genetic diseases. Their innovative approaches, extensive pipeline, collaborative partnerships, and patient-centric approach make them a prominent player in the biotechnology industry.
The company's portfolio includes multiple product candidates at different stages of development, ranging from early-stage research to late-stage clinical trials. BridgeBio Pharma is involved in various therapeutic areas, including oncology, cardiology, dermatology, neurology, endocrinology, and more. Their extensive pipeline includes potential treatments for diseases like genetic dermatology disorders, genetic cardiac diseases, lysosomal storage disorders, and various types of cancer.
One of the distinctive features of BridgeBio Pharma is its focus on genetically driven diseases that have limited treatment options or no approved therapies available. These genetic diseases are often caused by specific mutations or gene abnormalities, and BridgeBio Pharma's approach is to develop targeted therapies that can correct or mitigate these genetic defects. By using proprietary technologies and research capabilities, the company aims to uncover novel drug targets and develop innovative treatment strategies.
In addition to their internal research and development efforts, BridgeBio Pharma has established partnerships and collaborations with renowned academic institutions, pharmaceutical companies, and other biotech companies. This approach allows them to leverage external expertise, resources, and technologies to complement their own capabilities and accelerate the development of potential therapies.
BridgeBio Pharma applies a patient-centered approach to its drug development process. The company works closely with patient advocacy groups and aims to understand the specific needs of patients suffering from genetic diseases. By engaging with the patient community, BridgeBio Pharma seeks to bring meaningful and impactful therapies to market that can improve the lives of patients and their families.
As a publicly traded company, BridgeBio Pharma has a strong financial footing. The company has received significant investments from reputable investors, which provide the necessary capital for research and development activities. Furthermore, their collaborations with pharmaceutical companies also include financial support in the form of milestone payments and royalties.
In summary, BridgeBio Pharma Inc. is a biopharmaceutical company focused on providing therapeutic solutions for genetic diseases. Their innovative approaches, extensive pipeline, collaborative partnerships, and patient-centric approach make them a prominent player in the biotechnology industry.
As of the latest information, Bridgebio Pharma Inc. is a biotechnology company focused on developing and commercializing transformative medicines for genetic diseases and cancers. The company operates through various segments, products, and services, primarily categorized based on their therapeutic focus and technology platforms.
Segments
1. Genetic Diseases:
Bridgebio has a strong commitment to addressing genetic disorders, particularly those related to hereditary conditions. This segment includes the development of therapies for specific genetic mutations that can lead to severe health complications.
2. Oncology:
The oncology segment focuses on the development of drugs to treat various types of cancer. This includes both solid tumors and hematologic malignancies. The aim is to target the underlying genetic drivers of cancer to improve patient outcomes.
3. Product Pipeline:
Bridgebios pipeline consists of multiple candidates at various stages of development, ranging from preclinical trials to late-stage clinical trials. The emphasis is on identifying rare diseases where there is a significant unmet medical need.
Products
1. BBP-631:
This product targets certain genetic mutations responsible for fibrodysplasia ossificans progressiva (FOP), a rare and debilitating genetic condition. BBP-631 aims to reduce the formation of bone in areas where it is not normally present.
2. BBP-850:
Focused on treating vascular Ehlers-Danlos syndrome, BBP-850 is designed to stabilize blood vessels and prevent life-threatening complications associated with this genetic disorder.
3. BBP-398:
A targeted therapy aimed at cancers with specific genetic alterations, BBP-398 is in clinical stages for several oncology indications. Its mechanism is designed to disrupt the pathways that allow cancer cells to survive and proliferate.
4. AKCEA-APOCIII-LRx:
In collaboration with Akcea Therapeutics, this product targets triglyceride levels and has implications for cardiovascular disease treatment, addressing a significant area of need in patients with dyslipidemia.
5. Other Pipeline Products:
Bridgebio is continuously exploring new therapeutic candidates, which may include small molecules, gene therapies, and biologics. They prioritize development based on the potential to meet unmet medical needs in both genetic diseases and oncology.
Services
1. Research and Development:
Bridgebio Pharma engages in extensive R&D activities, applying cutting-edge technology and scientific expertise to advance its pipeline. This includes collaborations with academic institutions and other biotech companies to leverage external expertise.
2. Clinical Trials Management:
The company has established robust systems for managing clinical trials, ensuring compliance with regulatory standards while gathering valuable data on the safety and efficacy of their therapies.
3. Patient Engagement:
Bridgebio emphasizes the importance of patient-centric approaches by fostering communication with patients, caregivers, and healthcare providers. They aim to ensure that patient perspectives inform drug development processes.
4. Regulatory Affairs:
The company is actively involved in securing regulatory approvals for its therapies, navigating complex requirements from entities like the FDA and EMA. This includes submitting data for new drug applications (NDAs) and orphan drug designations.
5. Commercialization Strategies:
Bridgebio is focused on building effective commercialization plans for its products, including market access strategies to ensure that patients can access their therapies once approved.
Through these segments, products, and services, Bridgebio Pharma aims to transform the landscape of medicine for patients suffering from genetic diseases and cancer, working to bring innovative solutions to the market while focusing on unmet medical needs.
Segments
1. Genetic Diseases:
Bridgebio has a strong commitment to addressing genetic disorders, particularly those related to hereditary conditions. This segment includes the development of therapies for specific genetic mutations that can lead to severe health complications.
2. Oncology:
The oncology segment focuses on the development of drugs to treat various types of cancer. This includes both solid tumors and hematologic malignancies. The aim is to target the underlying genetic drivers of cancer to improve patient outcomes.
3. Product Pipeline:
Bridgebios pipeline consists of multiple candidates at various stages of development, ranging from preclinical trials to late-stage clinical trials. The emphasis is on identifying rare diseases where there is a significant unmet medical need.
Products
1. BBP-631:
This product targets certain genetic mutations responsible for fibrodysplasia ossificans progressiva (FOP), a rare and debilitating genetic condition. BBP-631 aims to reduce the formation of bone in areas where it is not normally present.
2. BBP-850:
Focused on treating vascular Ehlers-Danlos syndrome, BBP-850 is designed to stabilize blood vessels and prevent life-threatening complications associated with this genetic disorder.
3. BBP-398:
A targeted therapy aimed at cancers with specific genetic alterations, BBP-398 is in clinical stages for several oncology indications. Its mechanism is designed to disrupt the pathways that allow cancer cells to survive and proliferate.
4. AKCEA-APOCIII-LRx:
In collaboration with Akcea Therapeutics, this product targets triglyceride levels and has implications for cardiovascular disease treatment, addressing a significant area of need in patients with dyslipidemia.
5. Other Pipeline Products:
Bridgebio is continuously exploring new therapeutic candidates, which may include small molecules, gene therapies, and biologics. They prioritize development based on the potential to meet unmet medical needs in both genetic diseases and oncology.
Services
1. Research and Development:
Bridgebio Pharma engages in extensive R&D activities, applying cutting-edge technology and scientific expertise to advance its pipeline. This includes collaborations with academic institutions and other biotech companies to leverage external expertise.
2. Clinical Trials Management:
The company has established robust systems for managing clinical trials, ensuring compliance with regulatory standards while gathering valuable data on the safety and efficacy of their therapies.
3. Patient Engagement:
Bridgebio emphasizes the importance of patient-centric approaches by fostering communication with patients, caregivers, and healthcare providers. They aim to ensure that patient perspectives inform drug development processes.
4. Regulatory Affairs:
The company is actively involved in securing regulatory approvals for its therapies, navigating complex requirements from entities like the FDA and EMA. This includes submitting data for new drug applications (NDAs) and orphan drug designations.
5. Commercialization Strategies:
Bridgebio is focused on building effective commercialization plans for its products, including market access strategies to ensure that patients can access their therapies once approved.
Through these segments, products, and services, Bridgebio Pharma aims to transform the landscape of medicine for patients suffering from genetic diseases and cancer, working to bring innovative solutions to the market while focusing on unmet medical needs.